A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid ...
BridgeBio Pharma has announced that long-term efficacy and safety data from the open-label extension of its Phase 3 ATTRibute-CM trial of transthyretin stabilizer acoramidis in ATTR-CM, along with ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma ...
BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster its financial position and support ...
About Attruby™ (acoramidis) INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $106 from $91 on March 18, ...
The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...
BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from ...
Shares of BridgeBio PharmaBBIO are up more than 160% this year as the small biotech company takes on drug behemoths PfizerPFE and Alnylam PharmaceuticalsALNY. Though the company is just 10 years old, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results